Search

The article focuses on the prevalence and impact of ocular allergies, as well as the perspectives of three specialists - an ophthalmologist, an optometrist, and an allergist-immunologist - on managing allergic conjunctivitis. It mentions the specialists discuss the allergic response and the importance of stabilizing the mast cell, the patient experience and the need for proactive screening for ocular symptoms, and the different treatment categories for eye itch relief.

The article discusses the prevalence of ocular allergies in the U.S. and the impact they have on patients' quality of life. It also provides insights from three specialists on how to manage ocular allergies, focusing on the allergic response, histamine release, and patient experience with many allergy sufferers enduring chronic discomfort and only seeking care at the more acute stage, and the need to ask about ocular symptoms specifically.

This article discusses the importance of allergy testing and immunotherapy in managing ocular allergies and improving patients' quality of life. Eye care professionals are encouraged to ask about other allergy symptoms and refer patients to allergists if their allergies are not well controlled or if their medications interact with other prescriptions. Allergy testing helps identify specific allergens, and allergen immunotherapy (AIT), also known as allergy shots, can desensitize the immune system to allergens over time. Sublingual immunotherapy (SLIT) is an emerging alternative to allergy shots. It is important to note that these treatments should be administered under the supervision of a qualified allergist. Patient education and collaboration with allergists are crucial in providing comprehensive care for patients. [Extracted from the article]

The article offers information on effective ocular allergy treatment options available in the field of ophthalmology and optometry. It mentions that these options have many different methods of action and modes of delivery. It discusses the allergy immunology models based on histamine, role of immunoglobulin E (IgE), and leukotrienes. It further highlights case studies addressing the challenging issues which confound eye care professionals and allergists.

The article offers information on various types of conjunctivitis in relation with its epidemiology and etiology. It mentions allergic conjunctivitis which are cause by type I immunoglobulin e (IgE) or mast cell reactions to allergens. It states that adenovirus is the most common virus that cause viral conjunctivitis. It says that clinicians need to remember that wearing gloves and hand washing is important in every examination of patients.

The article offers information on the TearScan MicroAssay System, advanced tear diagnostic platform for dry eye or ocular allergy diagnosis. The device tests and analyzes tear film biomarkers, measuring lactoferrin and IgE concentration in a patient's tear film to clinically determine dry eye conditions. Discussed are microassay test procedures and the related Clinical Laboratory Improvement Amendments (CLIA) regulation.

The article provides information on the primary allergic events encountered in optical practice and the available anti-allergy therapy. It mentions that interaction between immunoglobulin E (IgE) and antigen leads in mast-cell sensitisation, followed by degranulation and activation on exposure to allergen. It states that mast cells play an important role in allergy as degranulation releases some mediators, such as neutral protease, heparin and histamine.

The article discusses the clinical care of an eight-year-old girl who was diagnosed with atopic keratoconjunctivitis (AKC). The patient complained of intermittent episodes of redness and itching on her left eye for two years. Her symptoms suggest AKC, which is an immunoglobulin E-mediated allergic condition. In managing patients with allergic diseases, the initial step is to remove or reduce exposure to sensitizing agents. Stabilizing mast cells and preventing histamine release should also be considered. For this patient, loteprednol was administered, along with cyclosporine, fluoquinolone and gatifloxacin ophthalmic solution. The author concluded that loteprednol is an ideal agent for the chronic therapy of ocular surface inflammatory and allergic diseases.

The article reports the pharmaceutical company Novartis' attempt to create a diagnostic tool to cure allergic asthma with collaborating immunoglobulin E (lgE) and several clinical findings.

The article discusses food-induced allergenic reactions and elimination diets. Food-induced allergenic reactions that affect the immune system may be categorized as IgE mediated or non-IgE mediated. Allergenic proteins may have an impact on several autoimmune diseases. On the other hand, elimination diets get complicated by inadequate consumption of other foods and maintenance of nutritional status.

The article focuses on the study that examined the risk of food allergies to children, non-Hispanic blacks, and males through the use of specific immunoglobulin E (IgE).

The article provides information on the published study "Effects of Boiling on the IgE-Binding Properties of Tropomyosin of Shrimp (Litopenaeus vannamei)," which suggested that boiling will lessen shrimp allergen.

The article presents information related to the advancement in ocular allergy therapy. As reported, modern ocular allergy therapy, which started with the 1997 introduction of olopatadine, has significantly reduced the dosing frequency for topical medication. Olopatadine has reduced the standard four doses of a mast-cell stabilizer, plus another four doses of a topical antihistamine to a single medication twice a day.

This article presents information on various drugs. The monoclonal antibody treatment omalizumab has received a licence for treatment of severe allergic asthma. It works by blocking immunoglobulin E, a key cause of symptoms in allergic disease, and is given by subcutaneous injection once every 2-4 weeks, It has been found to reduce exacerbations and hospital admissions in patients with severe persistent asthma. An injectable form of the bisphosphonate ibandronate given once every three months has been shown to significantly increase bone mineral density at the lumbar spine versus once-daily oral ibandronate over two years.